Soleno Therapeutics, Inc. (SLNO) Earnings History
Annual and quarterly earnings data from 2012 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | 32.4% | 11.0% |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export SLNO earnings history in CSV or JSON format
Free sign-in required to download data
Soleno Therapeutics, Inc. (SLNO) Earnings Overview
As of March 2, 2026, Soleno Therapeutics, Inc. (SLNO) reported trailing twelve-month net income of $21M, reflecting +1.1% year-over-year growth. The company earned $0.38 per diluted share over the past four quarters, with a net profit margin of 0.1%.
Looking at the long-term picture, SLNO's historical earnings data spans multiple years. The company achieved its highest annual net income of $21M in fiscal 2025, representing a new all-time high.
Soleno Therapeutics, Inc. maintains positive profitability with, operating margin of 0.3%, and net margin of 0.1%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including AGIO (-$401M net income, -7.6% margin), VRTX ($3.68B net income, 0.3% margin), ASND (-$228M net income, -0.3% margin), SLNO has outperformed on profitability metrics. Compare SLNO vs AGIO →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $21M | +111.9% | $62M | $0.39 | 11.0% | 32.4% |
| 2024 | -$176M | -351.0% | -$188M | $-4.38 | - | - |
| 2023 | -$39M | -62.0% | -$41M | $-2.36 | - | - |
| 2022 | -$24M | +22.1% | -$24M | $-2.87 | - | - |
| 2021 | -$31M | -25.5% | -$32M | $-5.81 | - | - |
| 2020 | -$25M | +19.9% | -$32M | $-3.68 | - | - |
| 2019 | -$31M | -130.8% | -$23M | $-15.78 | - | - |
| 2018 | -$13M | +14.9% | -$14M | $-9.54 | - | - |
| 2017 | -$16M | -29.9% | -$12M | $-26.18 | - | - |
| 2016 | -$12M | +24.2% | -$14M | $-58.35 | -831.6% | -938.1% |
See SLNO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SLNO Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare SLNO vs AGIO
See how SLNO stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is SLNO growing earnings?
SLNO EPS of $0.38 reflects slowing growth at +1.1%, below the 5-year CAGR of N/A. TTM net income is $21M. Expansion rate has moderated.
What are SLNO's profit margins?
Soleno Therapeutics, Inc. net margin is +0.1%, with operating margin at +0.3%. Below-average margins reflect competitive or cost pressures.
How consistent are SLNO's earnings?
SLNO earnings data spans 2012-2025. The current earnings trend is +1.1% YoY. Historical data enables comparison across business cycles.